Fondaparinux-associated heparin-induced thrombocytopenia

European Journal of Haematology

Volumn 91, Issue 5, 2013, Pages 437-441

  Bhatt, Vijaya R ^a   Aryal, Madan R ^b   Shrestha, Rajesh ^c   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Reading Health System   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

Adrenal hemorrhage; Adrenal infarct; Fondaparinux; Heparin induced thrombocytopenia; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

FONDAPARINUX;

ARTICLE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM; SYSTEMATIC REVIEW;

ADRENAL HEMORRHAGE; ADRENAL INFARCT; FONDAPARINUX; HEPARIN-INDUCED THROMBOCYTOPENIA; LOW MOLECULAR WEIGHT HEPARIN; UNFRACTIONATED HEPARIN;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD PLATELETS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; POLYSACCHARIDES; THROMBOCYTOPENIA;

EID: 84885945493     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12179     Document Type: Article

References (21)

1. Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008;122:211-20.
2. Greinacher A. Immunogenic but effective: the HIT-fondaparinux brain puzzler. J Thromb Haemost 2011;9:2386-8.
3. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006;26:2386-93.
4. Warkentin TE, Sheppard JI, Sun JC, Jung H, Eikelboom JW. Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. J Thromb Haemost 2013;11:253-60.
5. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-44.
6. Warkentin TE, Davidson BL, Buller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011;140:366-73.
7. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl 2):e495S-530S.
8. Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 2013;368:737-44.
9. Bhatt VR, Aryal MR, James AO. Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia. N Engl J Med 2013;368:2333-4.
10. Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent) 2012;25:13-5.
11. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65.
12. Warkentin TE, Chakraborty AK, Sheppard JA, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thromb Haemost 2012;108:394-6.
13. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356:2653-5; discussion 2653-2655.
14. Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost 2008;6:1243-6.
15. Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost 2010;104:1071-2.
16. Modi C, Satani D, Cervellione KL, Cervantes J, Gintautas J. Delayed-onset heparin-induced thrombocytopenia type-2 during fondaparinux (Arixtra) therapy. Proc West Pharmacol Soc 2009;52:5-7.
17. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008;99:779-81.
18. Alsaleh KA, Al-Nasser SM, Bates SM, Patel A, Warkentin TE, Arnold DM. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol 2008;83:876-8.
19. Schindewolf M, Lindhoff-Last E. Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779-781). Thromb Haemost 2008;100:168-9; author reply 169-170.
20. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011;9(Suppl 1):105-17.
21. Pistulli R, Oberle V, Figulla HR, Yilmaz A, Pfeifer R. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia. Blood Coagul Fibrinolysis 2011;22:76-8.